AC Immune SA ACIU
AC Immune SA (Nasdaq: ACIU) is a CNS/neurology/psychiatry drug developer. Its lead program, ACI-7104.056, is in Phase 2 for early-stage Parkinson's disease. Its next catalyst on record is ACI-7104: FDA meetings on Part 2 (expansion) design of VacSYn (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ACI-7104 — FDA meetings on Part 2 (expansion) design of VacSYn (Q1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ACI-7104.056 (anti-a-syn active immunotherapy), VacSYn | early Parkinson's disease | vaccine | Phase 2 |
| ACI-24.060 (anti-Abeta active immunotherapy), ABATE, Takeda option | Alzheimer's disease; Down syndrome | vaccine | Phase 2 |
| ACI-35.030 (anti-pTau active immunotherapy, partnered) | Alzheimer's disease | vaccine | Phase 2 |
| ACI-19764 (NLRP3 inhibitor) | neurodegenerative disease | small molecule | Phase 1 |
| Morphomer Tau (Lilly collaboration) | Alzheimer's disease | small molecule | Pre-clinical |
| Morphomer a-syn | Parkinson's disease | small molecule | Pre-clinical |
| PI-2620 Tau-PET tracer / a-syn PET tracers | diagnostic imaging, AD/PSP/PD | small molecule | NA_NON_THERAPEUTIC |
Recent results and decisions
- Sep 23, 2026met VacSYn Part 1 met all primary endpoints (safety, tolerability, immunogenicity): 100% antibody response after three immunizations in 34 patients, CSF antibody penetration, target engagement signal.
The primary endpoints for Part 1 of the VacSYn trial of ACI-7104 were safety, tolerability and immunogenicity, all of which were met.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 CNS/neurology/psychiatry companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.